|
業務類別
|
Biotechnology |
|
業務概覽
|
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma. |
| 公司地址
| 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065 |
| 電話號碼
| +1 650 549-1400 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.jaspertherapeutics.com |
| 員工數量
| 22 |
| Mr. Herbert C. Cross |
Corporate Secretary, Chief Financial Officer and Principal Accounting Officer |
美元 476.10K |
30/03/2026 |
| Mr. Jeet Mahal |
Chief Executive Officer and President |
美元 481.30K |
07/01/2026 |
|
|
| Mr. Kurt von Emster, C.F.A. |
Independent Director |
30/03/2026 |
| Mr. Vishal Kapoor |
Independent Director |
30/03/2026 |
| Mr. Thomas G. Wiggans |
Executive Chairman of the Board |
07/01/2026 |
| Dr. Scott C. Brun, M.D. |
Independent Director |
30/03/2026 |
| Dr. Svetlana Lucas, PhD |
Independent Director |
30/03/2026 |
| Dr. Judith Shizuru, M.D.,PhD |
Director |
30/03/2026 |
| Mr. Christian W. Nolet |
Independent Director |
30/03/2026 |
|
|
|
|
